Navigation Links
Navitas Names Dr. Dean Gesme as Medical Director
Date:10/17/2007

DENVER, Oct. 17 /PRNewswire/ -- Navitas Cancer Rehabilitation Centers of America, Inc. (Navitas), the market leader in providing integrated and comprehensive cancer rehabilitation services, is pleased to announce the appointment of Dean H. Gesme, Jr., M.D. as Corporate Medical Director.

In addition to currently providing care as a medical oncologist in the Minneapolis/St. Paul area, Dr. Gesme has served as the Past-Chair of the National Coalition for Cancer Survivorship and is Past-Chair of the Clinical Practice Committee of the American Society of Clinical Oncology. He has been the Oncology Representative on the AMA CPT Advisory Panel dealing with physician coding, and payment issues. Dr. Gesme is board certified in Internal Medicine, Medical Oncology, and Medical Management. Dr. Gesme attended medical school at the University of Iowa and completed his residency training in Internal Medicine in San Francisco and his fellowship in Medical Oncology at the University of Minnesota.

"Navitas has a tremendous opportunity to serve cancer survivors and Dr. Gesme is perfectly suited to provide medical leadership to this vision," shared Paul Barnes, Ph.D., President and CEO for Navitas. "Dean has devoted his career to the patient advocacy community as well to the treatment of cancer patients. We are fortunate to have him join our management team at Navitas.

"I have been impressed by the clinical basis of the cancer rehabilitation program at Navitas," Dr. Gesme stated. "I look forward to the day where rehabilitation services for cancer patients are as much the standard of care as is true for cardiac and other areas of medicine. Cancer patients deserve no less. I look forward to contributing to the clinical research efforts at Navitas to make that happen."

About Navitas Cancer Rehabilitation Centers of America

Founded in 2003, Navitas Cancer Rehabilitation Centers of America (http://www.navi
'/>"/>

SOURCE Navitas Cancer Rehabilitation Centers of America
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... The 2015 ... in-depth study on the current state of the global Propanol market with a focus ... CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, ...
(Date:7/30/2015)... July 30, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... announced that its strategic partner VetStem Biopharma, Inc. ... study of AT-016, an adipose-derived allogeneic stem cell ... of osteoarthritis pain in dogs. The ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/30/2015)... ... ... of its 2015 growth plan and as a follow up to the recently announced expansion ... is pleased to announce that it has begun construction on a new Microbiological Laboratory. The ... strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific to raw ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... ... announced results from the RE-COVER(TM) study investigating dabigatran etexilate (150 mg ... patients with acute VTE. Results of the trial were presented ... published online in the New England Journal of Medicine .(1) ...
... , NEW YORK, Dec. 4 ... of its IL-3R targeting agents, SL-401 and SL-501, in both ... (CML) have been selected for poster presentation at the upcoming 51st ... held in New Orleans from December 5-8, 2009. The poster will ...
... , DALLAS, Dec. 3 ... Board: ACCP), today provided an update on its European commercial ... a debilitating side effect of radiation treatment and chemotherapy. MuGard ... countries, including the UK, Germany, Italy, Norway, Greece and Sweden. ...
Cached Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4
(Date:7/21/2015)... GOTHENBURG, Sweden , July 21, 2015 ... sensor FPC1025. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... out of the George Washington University (GW), published in ... Sciences ( PNAS ), reveals another piece of ... behavioral diseases such as autism. Anthony-Samuel LaMantia, Ph.D., professor ... Medicine and Health Sciences (SMHS) and director of the ...
... press credentials for the American Chemical Society,s 245th National Meeting ... New Year will be held April 7-11, 2013, in New ... and others expected to gather in the Crescent City for ... from astronomy to zoology ― the meeting will offer ...
... keep their cellular calcium concentration at a very low ... many critical cellular functions (an elevated calcium concentration over ... mechanisms ensure that calcium concentration quickly returns to its ... of cellular calcium regulation underlie almost all neurodegenerative diseases. ...
Cached Biology News:GW professor discovers new information in the understanding of autism and genetics 2Press registration opens for 2013 meeting of world's largest scientific society 2
...
...
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
Biology Products: